From Liraglutide to Tirzepatide: New Frontiers in Anti-Obesity Pharmacotherapy

Mohsen Zabihi

doi:10.18502/aptj.v5i3.20513

Mohsen Zabihi Traditional Pharmacy and Pharmaceutical Sciences research center, and Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

DOI: https://doi.org/10.18502/aptj.v5i3.20513

Keywords: Liraglutide; Tirzepatide; Obesity; GLP-1 Agonists; GIP Agonists; incretin

Abstract

Obesity is a global health challenge, with over one billion people affected worldwide. While lifestyle changes remain essential, pharmacological interventions have become increasingly crucial in managing this complex condition. This editorial explores the evolution of anti-obesity medications, from liraglutide to the more recent breakthroughs like semaglutide and tirzepatide. These drugs, especially the newer GLP-1 and dual GIP/GLP-1 receptor agonists, have shown remarkable efficacy—comparable to bariatric surgery in some cases. The discussion highlights not only their clinical benefits but also their mechanisms, limitations, and future potential. As science advances, the integration of these therapies into mainstream care could significantly transform obesity treatment and improve long-term health outcomes.